Expert Interviews
Advertisement
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Mara B. Antonoff, MD, FACS, discusses the organization's mission, the resources it offers, and her hopes for the future.
Dr. Liu unpacks key questions in the field, and the research that could address them.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.